Literature DB >> 19747630

Targeting Treg cells in situ: emerging expansion strategies for (CD4(+)CD25(+)) regulatory T cells.

Alwi Shatry1, Jackeline Chirinos, Michael A Gorin, Monica Jones, Robert B Levy.   

Abstract

Recognition of the ability of CD4(+)FoxP3(+) T cells (Treg) to influence the generation of peripheral immune responses has engendered enthusiasm for the development of strategies utilizing these cells to regulate immune responses in clinically important settings including transplantation, autoimmunity and cancer. A number of studies have reported effective regulation utilizing ex-vivo expansion approaches and subsequent transfer of Treg populations in experimental models. This commentary discusses recently emerging strategies to activate and expand Treg cells in situ which include antibodies, antigen presenting cells and the use of IL2 / anti-IL2 antibody complex. The development of reagents which can stimulate and / or remove Treg cells in situ would represent an important advance towards facilitating new opportunities to harness this compartment for the augmentation of 'wanted' or suppression of 'unwanted' immune responses. Simultaneous targeting of multiple molecules on Treg cells may ultimately enable more effective control of this regulatory sector.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747630      PMCID: PMC2744641          DOI: 10.1016/j.bbmt.2009.06.009

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  44 in total

1.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Authors:  Wayne R Godfrey; Ying G Ge; Darrin J Spoden; Bruce L Levine; Carl H June; Bruce R Blazar; Stephen B Porter
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

Review 2.  Regulatory T cells in ovarian cancer: biology and therapeutic potential.

Authors:  Brian Barnett; Ilona Kryczek; Pui Cheng; Weiping Zou; Tyler J Curiel
Journal:  Am J Reprod Immunol       Date:  2005-12       Impact factor: 3.886

3.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

Authors:  Isabel Barao; Alan M Hanash; William Hallett; Lisbeth A Welniak; Kai Sun; Doug Redelman; Bruce R Blazar; Robert B Levy; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

4.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Authors:  Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

5.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

6.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.

Authors:  Emmanuel Zorn; Erik A Nelson; Mehrdad Mohseni; Fabrice Porcheray; Haesook Kim; Despina Litsa; Roberto Bellucci; Elke Raderschall; Christine Canning; Robert J Soiffer; David A Frank; Jerome Ritz
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

7.  Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Hua Zhang; Kevin S Chua; Martin Guimond; Veena Kapoor; Margaret V Brown; Thomas A Fleisher; Lauren M Long; Donna Bernstein; Brenna J Hill; Daniel C Douek; Jay A Berzofsky; Charles S Carter; E J Read; Lee J Helman; Crystal L Mackall
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

8.  Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Authors:  Onur Boyman; Marek Kovar; Mark P Rubinstein; Charles D Surh; Jonathan Sprent
Journal:  Science       Date:  2006-02-16       Impact factor: 47.728

9.  Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.

Authors:  Petra Hoffmann; Ruediger Eder; Leoni A Kunz-Schughart; Reinhard Andreesen; Matthias Edinger
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

10.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

Authors:  Manuela Battaglia; Angela Stabilini; Maria-Grazia Roncarolo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

View more
  4 in total

1.  Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.

Authors:  Dietlinde Wolf; Henry Barreras; Cameron S Bader; Sabrina Copsel; Casey O Lightbourn; Brent J Pfeiffer; Norman H Altman; Eckhard R Podack; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-20       Impact factor: 5.742

2.  Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.

Authors:  Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O Lightbourn; Cameron S Bader; Warren Alperstein; Norman H Altman; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-08       Impact factor: 5.742

Review 3.  Nanomaterials for cancer immunotherapy.

Authors:  Wantong Song; Sara N Musetti; Leaf Huang
Journal:  Biomaterials       Date:  2017-09-17       Impact factor: 12.479

Review 4.  The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation.

Authors:  Sabrina Copsel; Dietlinde Wolf; Krishna V Komanduri; Robert B Levy
Journal:  Haematologica       Date:  2019-06-20       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.